Successful Entry Into Service of EUTELSAT KONNECT Satellite

Successful Entry Into Service of EUTELSAT KONNECT Satellite

  • Marking a major step in Eutelsat’s Connectivity strategy
  • Contributing to making 2021 a turning point in Fixed Broadband

PARIS–(BUSINESS WIRE)–
Regulatory News:

Eutelsat Communications (Euronext Paris: ETL) announces the successful entry into service of its new-generation EUTELSAT KONNECT High Throughput Satellite at the 7° East orbital position.

Launched aboard an Ariane rocket on 16 January 2020, the availability of EUTELSAT KONNECT had been delayed due to Covid-related interruptions in the roll-out of the ground segment, but having now completed its testing, this much anticipated spacecraft is now operational and will gradually ramp up with 80% of the capacity in service by year-end and 100% by March 2021.

EUTELSAT KONNECT is an all-electric satellite, built by Thales Alenia Space and the first to use Thales Alenia Space’s new Spacebus Neo platform. With 75 Gbps of capacity across a network of 65 spot-beams, it delivers significant resources for broadband services and sets a new benchmark for flexibility in High Throughput Satellites leading to optimized fill rates. EUTELSAT KONNECT also comes with compelling economics, with a cost per sellable Gbps substantially lower than for existing in-orbit assets.

Coverage will initially be split between Europe with circa 55% of the capacity focused on high-demand areas namely France, Italy, Germany, Spain, the UK, and Africa where it will considerably supplement and gradually replace the capacity leased from a third-party operator.

The availability of EUTELSAT KONNECT marks a major step in Eutelsat’s Connectivity strategy, contributing to making 2021 a turning point in Fixed Broadband. The entire French capacity on the satellite has already been contracted on a wholesale basis by Orange. Moreover, Eutelsat’s recent acquisition of BigBlu Broadband adds a retail pillar to its distribution network which will accelerate the ramp up of the satellite and prepare the ground for the entry into service of KONNECT VHTS in the course of fiscal year 2022-23.

About Eutelsat Communications

Founded in 1977, Eutelsat Communications is one of the world’s leading satellite operators. With a global fleet of satellites and associated ground infrastructure, Eutelsat enables clients across Video, Data, Government, Fixed and Mobile Broadband markets to communicate effectively to their customers, irrespective of their location. Around 7,000 television channels operated by leading media groups are broadcast by Eutelsat to one billion viewers equipped for DTH reception or connected to terrestrial networks. Headquartered in Paris, with offices and teleports around the globe, Eutelsat assembles 1,000 men and women from 46 countries who are dedicated to delivering the highest quality of service. For more about Eutelsat go to www.eutelsat.com

Media

Joanna Darlington

Tel.: +33 1 53 98 31 07

[email protected]

Marie Sophie Ecuer

Tel.: +33 1 53 98 32 45

[email protected]

Jessica Whyte

Tel.: +33 1 53 98 46 21

[email protected]

Investors

Joanna Darlington

Tel.: +33 1 53 98 31 07

[email protected]

Cédric Pugni

Tel.: +33 1 53 98 31 54

[email protected]

Alexandre Illouz

Tel.: +33 1 53 98 46 81

[email protected]

KEYWORDS: Africa France United Kingdom Spain Italy Europe Germany

INDUSTRY KEYWORDS: Internet Satellite Other Technology Technology Telecommunications

MEDIA:

LeoVegas exercises authorisation for share repurchases

PR Newswire

STOCKHOLM, Nov. 16, 2020/PRNewswire/ — The Board of Directors of LeoVegas has decided to exercise the authorisation to repurchase own shares granted to it by the company’s Annual General Meeting on 8 May 2020. LeoVegas intends to repurchase shares for an amount up to EUR 10,000,000. The share repurchases will be conducted on one or more occasions before the Annual General Meeting on 11 May 2021. The purpose is to optimise the company’s capital structure and create shareholder value by reducing the number of shares outstanding. The repurchased shares may also be used as payment for potential future acquisitions.

The share repurchase programme is being initiated in accordance with the authorisation granted by the shareholders at the Annual General Meeting (AGM) on 8 May 2020 to repurchase up to 10% of the total number of shares in the company before the 2021 AGM. This entails that a maximum of 10,165,297 shares may be repurchased. However, the company intends during the prescribed period of time to repurchase shares for a maximum amount of EUR 10,000,000. LeoVegas today owns no treasury shares. The repurchase program will be carried out in accordance with Nasdaq Stockholm’s regulation for issuers and the following conditions:

  1. Repurchases may be conducted on one or more occasions before the AGM on 11 May 2021.
  2. Repurchases shall be made at a price within the range of the highest purchase price and lowest selling price for the shares on Nasdaq Stockholm at any given time.
  3. A maximum of 25%, with the exception of block trades, of the average daily trading volume in the shares on Nasdaq Stockholm may be repurchased on any given trading day.
  4. Payment for the shares shall be made in cash.

LeoVegas shall report to Nasdaq Stockholm all repurchases of own shares that have taken place during the program no later than within seven trading days after the date of repurchase.

This information is such that LeoVegas AB (publ) is obligated to make public pursuant to the EU Market Abuse Regulation 596/2014. The information in this press release has been published through the agency of the contact persons set out below, at the time stated by LeoVegas AB’s (publ) news distributor Cision, upon publication of this press release. The persons indicated below can also be contacted for further information.

for further INFORMATION, please contact:


Gustaf Hagman, Group CEO
+46 (0) 8 410 367 66
[email protected]


Stefan Nelson, Group CFO
+356 993 942 68
[email protected]

Philip Doftvik, Director of Investor Relations and Corporate Finance
+46 73 512 07 20,
[email protected]

About leovegas mobile gaming group:

LeoVegas vision and position is “King of Casino”. The global group LeoVegas Mobile Gaming Group offers games on Casino, Live Casino, Bingo and Sport. The parent company LeoVegas AB (publ.) is located in Sweden and its operations are mainly located in Malta. The company’s shares are listed on Nasdaq Stockholm. 

www.leovegasgroup.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/leovegas-mobile-gaming-group/r/leovegas-exercises-authorisation-for-share-repurchases,c3237448

The following files are available for download:


https://mb.cision.com/Main/17434/3237448/1335346.pdf

LeoVegas exercises authorisation for share repurchases

 

Cision View original content:http://www.prnewswire.com/news-releases/leovegas-exercises-authorisation-for-share-repurchases-301173404.html

SOURCE LeoVegas Mobile Gaming Group

Oppenheimer Accelerates Growth of Consumer Investment Banking Group with Appointment of James Murray as Managing Director, Based in London, United Kingdom

PR Newswire

NEW YORK and LONDON, Nov. 16, 2020 /PRNewswire/ — Oppenheimer & Co. Inc. (“Oppenheimer”), a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced the continued build-out of the leadership team within the Consumer Group of its investment banking business.  Oppenheimer is pleased to announce the appointment of James Murray as a Managing Director within its Global Consumer Investment Banking Group.  James will be based in London and report to Max Lami, European Chief Executive, and Emmanuel Durand, Global Head of Consumer Investment Banking.

James joins Oppenheimer with over 20 years’ experience in providing strategic advice to an extensive range of consumer clients.  He will be focused on both the UK and the Continent and will work closely with Jeroen Van Den Heuvel, Managing Director in the Consumer Investment Banking Group.  Together, Mr. Murray and Mr. Van Den Heuvel bring more than 40 years of collective mergers & acquisitions (“M&A”) and capital raising experience in the Consumer sector.

James holds an MBA from Imperial College, London and an MA from The University of St Andrews.

James started his investment banking career at Rothschild & Co in London, and prior to joining Oppenheimer was a Partner and Head of Consumer M&A at KPMG.  James has advised on over 50Bn USD worth of closed transactions, representing private and public companies, entrepreneurs and private equity clients.

Mr. Durand said, “We are thrilled to welcome James to our global team. His respected industry insight, experience and relationships in the Consumer sector complement those of Jeroen van den Heuvel.  He will enhance Oppenheimer’s capabilities in the U.K. and in continental Europe.  James will also be instrumental, together with Jeroen, in further consolidating our well established cross-border capabilities, notably strengthening the bridge with the US Consumer team.”

Mr. Lami added, “Oppenheimer is committed to the continued expansion of its Investment Banking capabilities in Europe and to servicing the needs of its clients by providing coverage across different geographies on an integrated basis. We are thrilled to be able to strengthen our business with James’ appointment to our team.”

Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions. For more information, please visit www.oppenheimer.com.

Oppenheimer Europe Limited
Oppenheimer Europe Limited is authorised and regulated by the Financial Conduct Authority and a Member firm of the LSE, providing advice to professional clients across Equities, Fixed Income and Corporate finance advisory. For more information please visit www.oppenheimer.com.

Media Contact:

Joseph Kuo / Michael Dugan
Haven Tower Group LLC
424 317 4851 or 424 317 4852
[email protected] or [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/oppenheimer-accelerates-growth-of-consumer-investment-banking-group-with-appointment-of-james-murray-as-managing-director-based-in-london-united-kingdom-301173270.html

SOURCE Oppenheimer & Co. Inc.

GENFIT: Third Quarter 2020 Financial Information and Launch of Renegotiation of Convertible Bond

  • Cash and cash equivalents of €199.3 million as of September 30, 2020
  • Company proposes a partial buyback and an amendment of the existing terms of the 2022 OCEANEs  

                   

Lille (France), Cambridge (Massachusetts, United States), November 16, 2020
– GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced its cash position as of September 30, 2020 and revenues for the first nine months of 20201, and proposes to 2022 OCEANEs holders a partial buyback and an amendment of the existing terms.

Cash Position

As of September 30, 2020, the Company’s cash and cash equivalents amounted to €199.3 million compared with €303.0 million one year earlier.

As of June 30, 2020, cash and cash equivalents totaled €225.7 million.

Revenues2

Revenues for the first nine months of 2020 amounted to €350 thousand compared to €31 million for the same period in 2019.

Revenues for the 3rd quarter resulted mainly from services provided and revenues under the licensing and collaboration agreements signed with Labcorp and Terns Pharmaceuticals.

Recap

On September 30, 2020, GENFIT announced its plan to reduce its cash burn by more than 50% by 2022 compared to the cash burn prior to the RESOLVE-IT Phase 3 data.

GENFIT confirms its objective to reduce the current cash burn rate from €110 million annually before our Phase 3 data, to approximately €45 million annually, beginning in 2022. Due to the residual expenses related to the termination of RESOLVE-IT and the workforce restructuring plan, 2021 will be a transition year from a cash burn standpoint.

This plan incorporates the following key components:

•     The overall clinical development program for elafibranor in NASH and all activities associated with the commercial launch of elafibranor in NASH have been terminated given the low probability of success compared to required expenses. The termination includes the NASH combination therapy trials, the pediatric trials, and other trials such as the evaluation of the impact of elafibranor on liver fat composition;

•     A comprehensive cost-saving plan has been implemented, including the redirection of R&D activities and the termination of secondary programs such as the RORgT program;

•     A workforce restructuring plan is underway to reduce the overall workforce by 40%, encompassing both the U.S and France in order to align the company size to the new scope of activity. The Company expects the plan to be completed by the end of the year.

Partial buyback and amendment of the terms of the 2022 OCEANEs

Pascal Prigent, CEO of GENFIT, commented: “The partial buyback and amendment of the terms of our convertible bonds, the terms of which are described below, aim to reduce by more than 50% the nominal amount of GENFIT’s financial debt, and to defer the maturity date of the remainder until 2025. We can allocate a maximum of €50 million to this transaction which will help the company maximize its chances of success in the interest of all stakeholders involved: the Company, its shareholders and bondholders. I am confident that through a constructive discussion with our bondholders we will find an acceptable compromise which will put the Company in a good position following the results of our Phase 3 PBC trial”.

Main terms of the October 2022 OCEANEs

In October 2017, GENFIT (the “Company”) issued 6,081,081 bonds convertible into new shares and/or exchangeable for existing shares due on October 16, 2020 for a nominal amount of €179,999,997.60 (“2022 OCEANEs”) by way of a private placement to institutional investors.

The 2022 OCEANEs were issued at a nominal unit value of €29.60 and bear interest at an annual nominal rate of 3.50%, payable semi-annually in arrears on April 16 and October 16 of each year.

The 2022 OCEANEs entitle their holders to receive new and/or existing GENFIT shares at an initial conversion/exchange ratio of one share per 2022 OCEANE.

The 2022 OCEANEs trade on Euronext Access (ISIN: FR0013286903).

Company objectives

Despite the Company’s significant cost savings initiatives, the expected cash position on the maturity date of the 2022 OCEANEs will not allow the Company to repay the convertible bonds at par. This represents a significant hurdle to the Company’s development and the pursuit of its new strategy, with adverse consequences in several areas: access to funding, signing of commercial agreements or strategic partnerships.

Therefore, this situation represents a major constraint for the Company and all the stakeholders: the 2022 OCEANE holders, shareholders, financial and commercial partners.

The Company’s significant efforts to preserve its cash must therefore be accompanied by an amendment of the terms and conditions of the 2022 OCEANEs.

Natixis and Kepler Cheuvreux (the “Counsels”) have been appointed by the Company to assist in this partial buyback and the amendment of the terms of the 2022 OCEANEs.

The Company and its Counsels have prepared a proposal encompassing a partial repurchase and an amendment of the terms of the 2022 OCEANEs, with the objective of:

  • preserving as much as possible the Company’s ability to finance its operations;
  • reducing the nominal amount of the financial debt to be redeemed;
  • deferring the maturity date of its convertible bonds in line with the next milestones in the Company’s two main programs: the ELATIVE™ Phase 3 clinical trial evaluating elafibranor in PBC and the NIS4 technology for (NASH) diagnosis; and
  • maximizing the potential for value-creation for shareholders and the 2022 OCEANE holders.

Proposal to the 2022 OCEANEs holders

In order to reach its objectives, the Company is considering proceeding in two interdependent phases:

      1)    Partial buyback of the 2022 OCEANEs

The Company is looking to reduce by more than 50% the nominal amount of the 2022 OCEANEs by repurchasing bonds that will then be cancelled. Considering the current cash level and the expected cash consumption over the coming years, the Company has allocated a maximum of €50 million to this objective. This envelope was determined to allow the continued operation of the Company’s business until the ELATIVE™ Phase 3 clinical trial evaluating elafibranor in PBC can be monetized.

All the repurchased 2022 OCEANEs will be bought back at the same price.

Should the buyback requests from the 2022 OCEANEs holders exceed the €50 million maximum repurchase amount contemplated by the Company, buyback requests will be reduced proportionally to ensure equal treatment among all the holders.

      2)    Amendment of the remaining portion (post partial buyback) of the terms of the 2022 OCEANEs

In order to pursue its strategy and maximize value creation for its shareholders and the 2022 OCEANEs holders, the Company proposes to amend the 2022 OCEANEs terms as described below:

  • a 3-year deferral of the maturity date (until October 16, 2025) which would reduce the financial pressure on the Company and give it the flexibility to decide on the optimal strategy to monetize results of the Phase 3 clinical trial ELATIVE™ evaluating elafibranor in PBC: direct commercial development or through partnerships, strategic alliances, etc.;
  • a deferral of the start of the early redemption period3 provided for in the 2022 OCEANEs terms and conditions (until November 3, 2023); and
  • an increase of the conversion ratio of the 2022 OCEANEs to be further determined, leading to an increased likelihood of conversion of the remaining portion of the 2022 OCEANEs, ultimately reinforcing the Company’s equity.

Implementation4

2022 OCEANE holders interested in the proposed partial buyback are invited to contact the Company or its Counsels. Retail holders should contact the 2022 OCEANE Bondholder Representative (Représentant de la Masse) at [email protected]

The Company will announce the definitive terms of the partial buyback as well as the amendments to the 2022 OCEANEs terms and conditions (in particular, the repurchase price offered for the 2022 OCEANEs and the contemplated conversion ratio) in a subsequent communication.

The Company and the 2022 OCEANE holders will then be able to enter into agreements relating to the 2022 OCEANE buyback, which will remain contingent on and occur after the following events:

  1. approval by the Extraordinary General Meeting of the Company’s shareholders of the new conversion ratio; and
  2. approval by the 2022 OCEANE holders of the aforementioned amendments.

As a final step, the Company will convene a general meeting of the shareholders and a general meeting of the 2022 OCEANE holders, which are expected to be held in the first quarter of 2021.

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in a Phase 3 clinical trial evaluating elafibranor in patients with primary biliary cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH.  NIS4™ technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements regarding our capacity to renegotiate the terms of our 2022 OCEANEs convertible bonds, our capacity to implement our restructuring plans, including a workforce restructuring plan, the impact of the  plans and negotiations on our capacity to significatively reduce, in the upcoming years, our operational expenses and our cash burn; in particular in a context of uncertainty related to the COVID-19 pandemic that could significatively affect our revenues projections, some operational expenses related to our clinical trials, and consequently, our projected cash burn.  The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements.  Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the French Autorité des marchés financiers (“AMF”), including those listed in Section 4 “Main Risks and Uncertainties” of the Company’s 2019 Universal Registration Document filed with the AMF on May 27, 2020 under n° D.20-0503, which is available on GENFIT’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s 20-F dated May 27, 2020. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.  These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | [email protected]

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | [email protected]

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com


1
Unaudited financial information under IFRS

2
Revenue recognized under IFRS 15

3
Early redemption event at the Company’s option which may encourage the conversion of the OCEANEs into shares in the event the Company’s share price exceeds 150% of the conversion price over a specified period.

4
At this stage, the renegotiation of the 2022 OCEANE terms remains in draft form.


 

Attachment



Nordic Nanovector ASA: Invitation to Q3 2020 Results Presentation and Webcast

PR Newswire

OSLO, Norway, Nov. 16, 2020 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the third quarter 2020 on Thursday, 19 November 2020.

A presentation by Nordic Nanovector’s senior management team will be webcast live the same day at 8:30am CET.

The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020 from 7:00am CET the same day.

For further information, please contact:

IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: [email protected]

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: [email protected]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa–invitation-to-q3-2020-results-presentation-and-webcast,c3237490

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-q3-2020-results-presentation-and-webcast-301173401.html

SOURCE Nordic Nanovector

Endeavour and Teranga Announce Combination to Create New Senior Gold Producer

ENDEAVOUR AND TERANGA ANNOUNCE COMBINATION TO CREATE NEW SENIOR GOLD PRODUCER

 HIGHLIGHTS:

· Creates a new top 10 senior gold producer with industry-leading low production costs and diversification across three countries

· Combines highly complementary assets with potential for significant synergies

· Strong cash flows and healthy balance sheet to fund attractive dividends and growth, whilst building a strong net cash position in 2021

· High potential for re-rating given potential best in class operating and financial metrics and attractive valuation compared to other senior gold producers

· Re-rating potential also underpinned by an enhanced capital markets profile with intention to seek a second listing on the London Stock Exchange as a Premium issuer targeting FTSE 100 entry

· Exchange ratio of 0.470x represents a premium of 5.1% based on the closing price on November 13, 2020, reflecting a balanced contribution from both sets of shareholders 

· Combination strongly supported by cornerstone shareholders with voting support agreements received

· La Mancha commits to inject $200 million in the combined entity

George Town & Toronto, November 16, 2020 – Endeavour Mining Corporation (“Endeavour”) (TSX:EDV) and Teranga Gold Corporation (“Teranga”) (TSX:TGZ; OTCQX:TGCDF) are pleased to announce that they have entered into a definitive agreement (the “Arrangement Agreement”) whereby Endeavour will acquire all of the issued and outstanding securities of Teranga by way of a Plan of Arrangement under the Canada Business Corporations Act (the “Combination”). Management will host a joint conference call and webcast today, at 8.30am Toronto time, 1.30pm London time (information provided in the section below).  

Existing Endeavour and Teranga shareholders will own approximately 66% and 34%, respectively, of the combined company on a fully diluted in-the-money basis. Pursuant to the Plan of Arrangement, Teranga common shares will be exchanged at a ratio of 0.470 Endeavour ordinary shares for each one Teranga common share (the “Exchange Ratio”). The Exchange Ratio represents a modest premium of 5.1% based on the closing price of Endeavour and Teranga’s shares on the TSX on November 13, 2020 and 9.4% based on the 20-day volume weighted average price of both companies for the period ended November 13, 2020.  

Sébastien de Montessus, President and CEO of Endeavour, said: “This combination offers an attractive opportunity to both sets of shareholders. By combining our complementary assets, we will enhance our strategic position on West Africa’s highly prospective Birimian Greenstone Belt and we will have the ability to deliver material synergies. The combined entity will become a new senior gold producer and enjoy an improved capital markets profile, underpinned by a healthy balance sheet and strong cash flow capabilities to support a sustainable dividend.

This transaction is immediately accretive to our shareholders on a NAV basis and broadly CFPS and EPS neutral over the next two years. It will be strongly accretive from 2023 when Sabodala-Massawa is ramped up into a top asset in the region while immediately adding geographic diversification into mining-friendly Senegal. The Wahgnion mine provides immediate cash flow and the rapidly advancing Golden Hill and Afema projects offer further growth optionality. The Teranga management team has done an outstanding job unlocking value and we
look forward to continuing to deliver returns for shareholders through the creation of a business with outstanding prospects.

Richard Young, President and Chief Executive Office of Teranga, said: “We have taken Teranga from a single asset producer to a low cost, mid tier gold producer over the past few years.  This combination with Endeavour, strongly supported by our two largest shareholders, allows Teranga shareholders to benefit from an improved valuation as owners of a best in class senior gold producer with among the lowest costs as well as among the best balance sheet, free cash flow yield, growth pipeline and dividend yield.”

Teranga is a low cost, mid tier gold producer in West Africa with two producing gold mines and an attractive growth pipeline in Senegal, Burkina Faso and Côte d’Ivoire. Teranga is expected to produce 533,000 ounces of gold per year at average all-in-sustaining costs of $785 per ounce over the next five years. Endeavour is a leading West African gold producer with six mines across Burkina Faso and Côte d’Ivoire with a production profile of over 1 million ounces at below $900 per ounce.

CREATES A NEW TOP 10 SENIOR GOLD PRODUCER WITH INDUSTRY-LEADING LOW PRODUCTION COSTS

  • The Combination creates a new top ten senior gold producer with average annual production of more than1.5Moz per year with industry-low production costs, as shown in Figures 1 and 2 below.
  • The combined entity will be diversified across six core operating mines in three countries, and strategically positioned as the largest gold producer in each of Senegal, Côte d’Ivoire and Burkina Faso.
  • It will also have an industry-leading development pipeline of six greenfield projects (Fetekro, Golden Hill, Afema, Kalana, Bantou and Nabanga) and the largest exploration portfolio across the underexplored West African Birimian Greenstone Belt.

                                                        Figure 1: 2021 Gold Production for Senior Gold Producers1                                         Figure 2: 2021 AISC for Senior Gold Producers1

         

    

COMBINES HIGHLY COMPLEMENTARY ASSETS WITH POTENTIAL FOR SIGNIFICANT SYNERGIES  

  • Ability to leverage Endeavour’s West African operating model to extract significant financing, operating and capital synergies across all of Teranga’s assets:
    • Sabodala-Massawa, in Senegal, to become a flagship asset alongside Ity and Houndé with the potential to become a top tier asset given its high grade, low cost, long mine life, large reserves and significant exploration potential
    • Wahgnion, in Burkina Faso, to add immediate production and cash flow diversification, benefiting from significant operating cost and efficiency synergies as part of Endeavour’s West African platform with the potential to unlock additional value through exploration and asset optimization
    • Golden Hill, an advanced exploration project in Burkina Faso, is situated within trucking distance of Endeavour’s Houndé mine and offers potentially significant capital and operating synergies through its development as a satellite operation
    • Afema is a very rapidly advancing and promising exploration project in Côte d’Ivoire, with strong exploration results expected to be announced in the coming weeks, as well as a maiden resource in the first quarter of 2021
  • Ability to leverage a strong integration platform already in place as, following its acquisition of SEMAFO on July 1, 2020, Endeavour completed a comprehensive evaluation of its organizational structure and capabilities, with a view to ensuring it was well positioned for future growth.  

ABILITY TO PAY ATTRACTIVE DIVIDENDS AND FUND GROWTH UNDERPINNED BY STONG BALANCE SHEET

  • The combined entity will immediately become a sustainable dividend payer, underpinned by a healthy balance sheet and expected robust free cash flow generation, following the combined building of three long life gold mines and the acquisition of the high grade Massawa project from Barrick, over the past several years.
  • La Mancha has committed to invest $200 million in support of the Combination to further strengthen the balance sheet.
  • The combined entity will benefit from a very robust balance sheet with $279 million of net debt2 and a net debt/LTM EBITDA ratio of 0.33x on a pro forma basis as at September 30, 2020. The combined entity expects to be in a net cash position by mid-2021, based on current gold prices.
  • As part of the Combination, a refinancing has been negotiated which will materially lower financing costs and offer a clean and simple debt structure. The refinancing of existing Endeavour debt as well as higher cost Teranga debt is expected to save the combined entity approximately $40 million per year over the next several years.
  • Endeavour has arranged an up-to $800 million fully-committed debt refinancing package on a certain funds basis (the “Refinancing”). Citi, HSBC Bank Canada, and ING Bank N.V. have fully underwritten the Refinancing on SunGard terms. The Refinancing will be used to consolidate existing debt instruments of both Endeavour (including the existing Endeavour RCF, under which $310 million is outstanding as of September 30, 2020) and Teranga (including the various facilities provided by Taurus Funds Management Pty Ltd, under which $374 million is outstanding4 as well as two offtake agreements). The Refinancing has been conservatively sized and may be reduced prior to closing at Endeavour’s discretion.
  • The first dividend declared by Endeavour on November 12, 2020 totaling $60 million for the 2020 fiscal year, set the path to a sustainable dividend policy. The dividend will be payable in early Q1-2021 to Endeavour shareholders as at a record date to be set before the Transaction close and equates to approximately $0.37 per share (C$0.48 per share) which represents a 1.6% yield based on Endeavour’s closing price on November 11, 2020. Following the payment of this first dividend, Endeavour expects to declare future dividends on a semi-annual basis, with the goal of maintaining a similar annual dividend yield until it has reached a targeted net cash position of $250 million. Once that target is reached, Endeavour will be in a position to re-assess its capital allocation priorities, which may include augmenting its shareholder return program.

HIGH POTENTIAL FOR SIGNIFICANT SHARE PRICE RE-RATING 

  • Both Endeavour and Teranga shareholders to benefit from potential re-rating driven by the creation of a new best-in-class senior gold producer with among the lowest costs and highest cash flow yield of the senior gold group. The combined company would also have competitive dividend yields, a well-structured balance sheet, and a robust organic growth pipeline, all of which are expected to close the valuation gap versus senior peer group, as shown in Figure 3.
  • The potential re-rating is also underpinned by an enhanced capital markets profile due to increased scale and liquidity to attract generalist investors with combined market capitalization of approximately $6 billion5.
  • Capital markets profile to be further enhanced with a future second listing on the London Stock Exchange as a Premium issuer to target FTSE inclusion in 2021. The combined entity is expected to be well positioned as the largest Premium LSE-listed pure gold producer.

            Figure 3: Senior Gold Producers Trading Multiples6

COMBINATION STRONGLY SUPPORTED BY CORNERSTONE SHAREHOLDERS  

Voting Support Agreements Received

  • The major shareholders of both Endeavour and Teranga strongly support the transaction. Voting support agreements have been received from Teranga’s largest shareholders, Tablo Corporation (“Tablo”) and Barrick Gold Corporation (“Barrick”) and from Endeavour’s largest shareholder, La Mancha Holding (“La Mancha”).
  • Tablo and Barrick, who together control approximately 33% of the outstanding shares of Teranga, have entered into voting support agreements pursuant to which they have agreed to vote their common shares in favor of the Combination. All of the directors and senior officers of Teranga have also entered into voting support agreements.
  • La Mancha, along with officers and directors of Endeavour, who together represent approximately 24% of the outstanding shares of Endeavour, have entered into voting support agreements pursuant to which they have agreed to vote their ordinary shares in favor of the Combination.

La Mancha Commits to Invest $200 Million in Support of Combination

  • La Mancha has committed to invest $200 million in support of the Combination to further strengthen the balance sheet, and help preserve the combined entities planned capital returns strategy. Following completion of the Combination and its investment, La Mancha’s shareholding will decrease from approximately 24% in Endeavour to approximately 19% in the combined entity (calculated on a pro forma basis using current share prices and exchange rates). This investment will strengthen the balance sheet of the combined entity and increase available liquidity, whilst the reduction in La Mancha’s shareholding will provide for a larger free float and greater stock liquidity. 
  • The placement is subject to TSX approval. The closing of the investment is expected to occur after the closing of the Combination and will be priced at the US dollar equivalent of a 5% discount to the 5-day volume weighed average price of Endeavour’s ordinary shares on the TSX as of November 23, 2020.
  • The Investor Rights Agreement between Endeavour and La Mancha has been amended where La Mancha will no longer have an anti-dilution right. In addition, La Mancha will continue to be entitled to nominate two directors to the Endeavour board provided that its shareholding remains above 15% and will be entitled to nominate one director if their holding is between 10 and 15%.  
  • The investment by La Mancha is considered to be a “related party transaction” for purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Endeavour is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101, respectively, in reliance on sections 5.5(a) and 5.7(b) of MI 61-101, respectively, as the fair market value of the investment is not more than the 25% of Endeavour’s market capitalization.

TRANSACTION APPROVALS AND TIMELINE

For Endeavour, pursuant to the rules of the TSX, the Combination will require approval by a simple majority of the votes cast by its shareholders. In addition, shareholders of Endeavour will be asked to approve the issuance of Endeavour ordinary shares to La Mancha pursuant to the terms of a subscription agreement entered into between Endeavour and La Mancha dated November 16, 2020. Such resolution will require the approval of a simple majority of votes cast by Endeavour shareholders.

For Teranga, the Combination will require the approval of 66 2/3% of votes cast by shareholders of Teranga and the approval of a simple majority of the votes cast by shareholders of Teranga, other than the shareholders required to be excluded under applicable laws, including Barrick Gold who is a syndicate member in Teranga’s facility with Taurus Funds Management Pty Ltd which is intended to be refinanced on closing.

Full details of the Combination will be included in the joint management information circular of Endeavour and Teranga, which is expected to be mailed to each company’s respective shareholders in December 2020. It is anticipated that both shareholder meetings and the closing of the Combination will take place in the first quarter of 2021.

BOARD, MANAGEMENT AND EMPLOYEES

The Board of Directors of Endeavour will be comprised of 10 directors, including 7 representatives from Endeavour and 3 from Teranga.

Sebastien de Montessus and his executive team will lead the combined group, with the support of key Teranga senior management.   

BOARD OF DIRECTORS’ RECOMMENDATIONS

Teranga appointed a special committee of independent directors to consider and make a recommendation with respect to the Combination. Based in part on the unanimous recommendation of the special committee of Teranga, the Arrangement Agreement has been unanimously approved by the Board of Directors of Teranga. The Arrangement Agreement has also been unanimously approved by the Board of Directors of Endeavour. Both Boards of Directors recommend that their respective shareholders vote in favor of the Combination.

Canaccord Genuity Corp has provided a fairness opinion to the Board of Directors of Teranga and Cormark Securities Inc. has provided a fairness opinion to the Special Committee of Teranga. Each fairness opinion stated that, as of the date thereof and, based upon and subject to the assumptions, limitations and qualifications stated in such opinion, the consideration received under the Arrangement Agreement is fair, from a financial point of view, to the Teranga shareholders. Scotiabank has provided a fairness opinion to the Board of Directors of Endeavour stating that, as of the date thereof and, based upon and subject to the assumptions, limitations, and qualifications stated in such opinion, the consideration to be paid by Endeavour to the shareholders of Teranga is fair, from a financial point of view, to Endeavour.

Mr. Naguib Sawiris, Chairman of the Board of Managers of La Mancha, abstained from voting as a director of Endeavour on the $200 million investment by La Mancha.

CONDITIONS AND OTHER PROVISIONS

In addition to shareholder and court approvals, the Combination is subject to applicable regulatory approvals including TSX and Investment Canada Act and Competition Act (Canada) approvals and the satisfaction of certain other closing conditions customary in combinations of this nature.

The Arrangement Agreement contains customary provisions including mutual non-solicitation provisions, a mutual right to match any superior proposal of the other party, a $40 million termination fee payable to Teranga under certain circumstances, and a $40 million termination fee payable to Endeavour under certain circumstances.

In addition to other customary closing conditions under the Arrangement Agreement, there is a closing condition in favor of Endeavour that it shall be provided by Franco-Nevada (Barbados) Corporation a waiver and consent in respect of certain change of control and other requirements under the amended and restated gold purchase and sale agreement, dated May 1, 2019, among, amongst others, Franco-Nevada (Barbados) Corporation, Teranga and Teranga Gold (B.V.I.) Corporation, in form and substance satisfactory to Endeavour, acting reasonably.

ADVISORS AND COUNSELS

Gleacher Shacklock LLP and Scotiabank are acting as financial advisors to Endeavour with McCarthy Tétrault LLP and Linklaters LLP acting as Endeavour’s legal advisors.

Cormark Securities Inc., Cutfield Freeman & Co. Ltd. and Canaccord Genuity Corp. are acting as financial advisors to Teranga with Stikeman Elliott LLP acting as Teranga’s legal advisor.

Blake Cassels & Graydon LLP acted as the legal advisor to Teranga’s Special Committee.

Stanhope Capital LLP acted as financial advisor to Tablo Corporation.

Norton Rose Fulbright Canada LLP acted as legal advisor to La Mancha.

CONFERENCE CALL AND LIVE WEBCAST

Endeavour and Teranga management will jointly host a conference call and webcast on Monday, November 16, at 8:30am. Toronto time, to discuss the Combination.

The conference call and webcast are scheduled at:

5:30am in Vancouver
8:30am in Toronto and New York
1:30pm in London
9:30pm in Hong Kong and Perth

The webcast can be accessed through the following link:

https://webcast.merchantcantoscdn.com/webcaster/dyn/4000/7464/16532/124738/Lobby/default.htm

Analysts and investors are also invited to participate and ask questions using the dial-in numbers below and quoting “Endeavour / Teranga Transaction”:

Standard International Access: +44 (0) 20 3003 2666
Canada Toll Free: 1-866-378 3566
UK Toll Free: 0808 109 0700
US Toll Free: 1-866-966-5335

The conference call and webcast will be available for playback on Endeavour’s website.

ABOUT ENDEAVOUR

Endeavour Mining is a multi-asset gold producer focused on West Africa, with two mines (Ity and Agbaou) in Côte d’Ivoire, four mines (Houndé, Mana, Karma and Boungou) in Burkina Faso, four potential development projects (Fetekro, Kalana, Bantou and Nabanga) and a strong portfolio of exploration assets on the highly prospective Birimian Greenstone Belt across Burkina Faso, Côte d’Ivoire, Mali and Guinea.   

As a leading gold producer, Endeavour Mining is committed to principles of responsible mining and delivering sustainable value to its employees, stakeholders and the communities where it operates. Endeavour is listed on the Toronto Stock Exchange, under the symbol EDV.

ABOUT TERANGA

Teranga is a mid-tier gold producer operating long-life, low-cost mines and advancing prospective exploration properties across West Africa, one of the world’s fastest growing gold jurisdictions. The top-tier gold complex created by integrating the recently acquired high-grade Massawa project with Teranga’s Sabodala mine, the successful commissioning of Wahgnion, Teranga’s second gold mine, and a strong pipeline of early to advanced-stage exploration assets support the continued growth of Teranga’s reserves, production and cash flow. Through its continued success and commitment to responsible mining, Teranga creates sustainable value for all stakeholders and acts as a catalyst for social, economic, and environmental development. For more information about Teranga, please go to terangagold.com.

CONTACT INFORMATION

For further information, please contact:

Endeavour Mining Corporation

Martino De Ciccio

VP – Strategy & Investor Relations
+44 203 640 8665
[email protected]

Vincic Advisors in Toronto

John Vincic, Principal

+1 (647) 402 6375
[email protected]


Brunswick Group LLP in London

Carole Cable, Partner
+44 7974 982 458
[email protected]

Teranga Gold Corporation

Trish Moran

VP, Investor Relations
& Corporate Communications
+1-416-607-4507
[email protected]
 

The Toronto Stock Exchange has neither reviewed nor accepts responsibility for the adequacy or accuracy of this news release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Endeavour and Teranga with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and include information regarding: (i) expectations regarding whether the proposed Combination will be consummated, including whether conditions to the consummation of the Combination will be satisfied, or the timing for completing the Combination, (ii) expectations regarding the initial dividend and the Company’s future dividend policy and the effects thereof, (iii) expectations for the effects of the Combination or the ability of the combined company to successfully achieve business objectives, including integrating the companies or the effects of unexpected costs, liabilities or delays, (iv) the potential benefits and synergies of the Combination, (v) expectations regarding whether the proposed La Mancha investment will be consummated or the timing for completing the proposed investment and (vi) expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect Endeavour’s and Teranga’s respective management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Endeavour and Teranga believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to consummate the Combination; the ability to obtain requisite regulatory and shareholder approvals and the satisfaction of other conditions to the consummation of the Combination on the proposed terms and schedule; the ability of Endeavour and Teranga to successfully integrate their respective operations and employees and realize synergies and cost savings at the times, and to the extent, anticipated; the potential impact on exploration activities; the potential impact of the announcement or consummation of the Combination on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; the re-rating potential following the consummation of the Combination; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Combination. This forward-looking information may be affected by risks and uncertainties in the business of Endeavour and Teranga and market conditions. This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in filings made by Endeavour and Teranga with the Canadian securities regulators, including Endeavour’s and Teranga’s respective annual information form, financial statements and related MD&A for the financial year ended December 31, 2019 and September 30, 2020 filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Endeavour and Teranga have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Endeavour and Teranga do not intend, and do not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

NON-IFRS FINANCIAL MEASURES

The information in this news release includes the following non-IFRS financial measures: all-in sustaining costs per ounce of gold sold (“AISC)”, cash costs per ounce of gold sold, and free cash flow. These financial measures do not have any standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other issuers, even as compared to other issuers who may also be applying the World Gold Council (“WGC”) guidelines, which can be found at http://www.gold.org. Management of Endeavour and Teranga believe that the use of these non-IFRS measures will assist analysts, investors and other stakeholders of the companies in understanding the costs associated with producing gold, understanding the economics of gold mining, assessing the companies’ operating performance, the combined company’s ability to generate free cash flow from current operations and to generate free cash flow on an overall company basis, and for planning and forecasting of future periods. However, AISC does have limitations as an analytical tool as it may be influenced by the point in the life cycle of a specific mine and the level of additional exploration or expenditures a company has to make to fully develop its properties. Accordingly, these non-IFRS measures should not be considered in isolation, or as a substitute for, analysis of the companies; results as reported under IFRS. A reconciliation of certain the non-IFRS measures presented in this news release is contained in Endeavour’s most recently filed annual MD&A, which is available on SEDAR at www.sedar.com.

ENDEAVOUR QUALIFIED PERSON

Clinton Bennett, Endeavour’s Vice-President of Metallurgy and Process Improvement – a Fellow of the Australasian Institute of Mining and Metallurgy, is a “Qualified Person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) and has reviewed and approved the technical information in this news release related to Endeavour.

TERANGA QUALIFIED PERSON

Stephen Ling, P.Eng., who is a member of the Professional Engineers Ontario, is Teranga’s Director of Technical Services. Mr. Ling is a “Qualified Person” under NI 43-101 Standards of Disclosure for Mineral Projects. Mr. Ling has consented to the inclusion in this document of the matters based on his compiled information in the form and context in which it appears in this document related to Teranga.

LA MANCHA – EARLY WARNING REPORT

As date hereof, La Mancha Holding S.à r.l., indirectly through La Mancha Africa Holding Limited, owns 39,329,731 ordinary shares of Endeavour, representing approximately 24% of the issued and outstanding ordinary shares of Endeavour.

The La Mancha investment commitment in Endeavour is being undertaken for investment purposes and La Mancha may, from time to time, acquire additional securities of Endeavour or dispose of all or a portion of the ordinary shares of Endeavour previously acquired or held.

An early warning report containing additional information with respect to the foregoing matters will be filed under Endeavour’s SEDAR profile at www.sedar.com.

For further information: A copy of the early warning report may be obtained by contacting: Tariq Qureshi, 125 Kensington High Street, London, W8 5SF; tel: +44 (0) 2030534299.


1 2021E Gold production and AISC based on average 2021 fiscal year estimates published by equity research analysts. Combined Entity based on analyst estimates for Endeavour and Teranga. Harmony AISC represents fiscal year 2020 actual figure.

2 Pro forma based on latest available public information, net of the proposed $200 million La Mancha investment and gold bullion unsold as at September 30, 2020 at Teranga (valued at $39 million as per Teranga Q3-2020 MD&A)

3Combined Entity LTM EBITDA as at September30, 2020 of $867 million

4 $391 million outstanding as at September 30, 2020, with subsequent repayment of further $17.1 million as per Teranga Q3-2020 MD&A

5 Market capitalizations of Endeavour and Teranga using fully diluted in-the-money number of shares, closing share prices on the TSX as at November 13, 2020 and US$/C$ exchange rate of 1.3161 and including the proposed La Mancha investment of $200 million

6 FCF 2021, EBITDA 2021, NAV estimates for peers sourced from CapitalIQ as at November 13, 2020. Combined Entity based on average of equity research analyst estimates for both Endeavour and Teranga

 

Attachments



Equinor ASA: Changes in Equinor’s corporate structure and Corporate Executive Committee

Equinor (OSE: EQNR, NYSE: EQNR) announces changes in the corporate structure and the Corporate Executive Committee (CEC).

“Equinor is developing as a broad energy company. We are now making changes to further strengthen our ability to deliver on our always safe, high value, low carbon strategy. These changes will support improved value creation from our world-class oil and gas portfolio, accelerated profitable growth within renewables and the development of low carbon solutions,” says Anders Opedal, President and CEO of Equinor.

Organisational structure

The new corporate structure will consist of six business areas and five corporate centre units. The current organisational structure will remain in place until the planned implementation takes effect by 1 June 2021.

Business Areas:

Exploration & Production Norway (EPN) and Exploration & Production International (EPI) are established as two new business areas. They will continue competitive and resilient oil and gas exploration and production, with industry-leading unit costs, recovery rates and carbon efficiency. Equinor is well positioned with world-class assets in attractive areas. Two consolidated oil and gas business areas will support a focused approach to strengthen value creation and reduce emissions.

Renewables (REN) continues as a business area, renamed from New Energy Solutions (NES), aiming to accelerate profitable growth within renewables. It will report as a separate segment from the first quarter of 2021.

Equinor is establishing Technology, Digital & Innovation (TDI) as a separate business area, while Projects, Drilling & Procurement (PDP) will become a more focused business area. Technology, digitalisation and innovation are fundamental enablers to improve safety, increase value creation, reduce emissions and develop low carbon solutions. Gathering units in a new TDI business area will unlock opportunities both within oil and gas, renewables and low carbon solutions.

Marketing, Midstream & Processing (MMP) is unchanged as a business area.

Corporate centre units:

The Corporate Finance Organisation (CFO) will also include units for strategy, mergers & acquisitions and business development.

Safety, Security & Sustainability (SSU) will be established as a new functional area.

Legal & Compliance (LEG), Communication (COM) and People & Organisation (PO) will remain as functional areas.

The announced changes in the corporate structure will support continuous improvement and reduce the overall number of leadership positions but does not in itself lead to redundancies.

Corporate Executive Committee

“The changes in the CEC team reflect a good mix of continuity and renewal, diversity and experience from across Equinor and the industry. With this new team and a highly competent organisation, we are ready to take Equinor forward together,” says Opedal.

Equinor’s Corporate Executive Committee will be as follows from 1 June 2021:

  • President and Chief Executive Officer (CEO) Anders Opedal.
  • Chief Financial Officer (CFO), Executive Vice President (EVP) Svein Skeie (Acting).
  • Exploration & Production Norway (EPN), EVP Kjetil Hove.
  • Exploration & Production International (EPI), EVP Al Cook.
  • Marketing, Midstream & Processing (MMP), EVP Irene Rummelhoff.
  • Renewables (REN), EVP Pål Eitrheim.
  • Projects, Drilling & Procurement (PDP), EVP Arne Sigve Nylund.
  • Technology, Digital & Innovation (TDI), EVP Carri Lockhart.
  • Safety, Security & Sustainability (SSU), EVP Jannicke Nilsson.
  • Legal & Compliance (LEG), EVP Siv Helen Rygh Torstensen.
  • People & Organisation (PO), EVP Ana Fonseca Nordang.

The Senior Vice President (SVP) for Communication (COM) will report to the CEO and participate in the CEC as today. Jannik Lindbæk is appointed SVP COM from 1 January 2021.

The Corporate Executive Committee will be based in Norway.

The organisation structure will remain the same as it is today with a few key adjustments to ensure continuity and safe operations through the transition period from 1 January 2021 to 1 June 2021.

  • Kjetil Hove will step into the role as EVP Development & Production Norway (DPN) from 1 January 2021.
  • Al Cook will step into the role as EVP Development & Production International (DPI), and the existing Development & Production Brazil (DPB) and Global Strategy & Business Development (GSB) will be part of DPI from 1 January 2021.
  • Arne Sigve Nylund will step into the role as EVP Technology, Projects and Drilling (TPD) from 1 January 2021.

As previously announced, EVP Margareth Øvrum will retire 31 December 2020 and SVP Reidar Gjærum will step into a Senior Advisor role in the CEO Office 1 January 2020. Geir Tungesvik, who has been acting as executive vice president for Technology, Projects, and Drilling (TPD) will return to his role as senior vice president of Projects (PRD) 1 January 2021. Tore Løseth will continue as acting EVP for Exploration until 1. June 2021.

EVP Torgrim Reitan has decided to step down as EVP Development & Production International to take on a new position within Equinor. He has been a member of the CEC since 2011 as Chief Financial Officer, EVP for Development & Production USA and EVP for Development & Production International. From 1 January 2021, he will take on the role as SVP Finance & Control in the Renewables business area, supporting the ambition to accelerate profitable growth in renewables.

“I would like to thank Torgrim for his strong contributions as a member of the executive leadership team for a decade. It was under his leadership forceful actions were taken to improve profitability, improve safety performance and solve internal control problems in the US business. His experience and competence will be a tremendous asset to further accelerate and realise our ambitions within renewables in Equinor. I would also like to thank Geir for his contribution to the CEC as acting EVP for TPD,” says Opedal.

Carri Lockhart is a U.S. citizen and joined Equinor in 2016. She comes from the position as Senior Vice President Portfolio & Partner Operated in Development & Production International, which she has held since August 2018.

Prior to this, Lockhart was Senior Vice President for Equinor’s U.S. Offshore business. Lockhart started her career with Marathon Oil as a reservoir engineer in Anchorage, Alaska. Lockhart has held a variety of leadership roles across the upstream organization with experience in offshore, onshore conventional and unconventional assets, field supervision, facilities construction and operations, international country management, strategic planning and business development.

Lockhart has a Bachelor of Science degree in Petroleum Engineering from Montana College of Mineral Science and Technology.

Kjetil Hove is a Norwegian citizen and joined Norsk Hydro in 1991. He comes from the position as Senior Vice President Field Life Extension, which he has held since January 2020.

Prior to this, Hove was Senior Vice President for Operations Technology in Development & Production Norway. Hove started his career in Norsk Hydro within petroleum technology holding various positions within exploration, field development and operations in Norway. Hove has held a variety of leadership roles, including Vice President international business development, country manager Brazil, and Senior Vice President Operations West in Development & Production Norway.
Hove has a master’s degree in petroleum engineering from Norwegian University of Science and Technology (NTNU).

Jannik Lindbæk is a Norwegian citizen and joined Equinor in 2010. He comes from the position as Vice President Corporate Communication Political & Public Affairs Norway, which he has held since August 2019.

Prior to this, Lindbæk was Equinor’s Vice President for communication in Brussels, in Media Relations, and in the CFO Global Business Services. Before joining Equinor, Lindbæk was SVP Corporate Communication in Aker Solutions, PR manager in Microsoft and PR consultant in BWPR and GCI Monsen.
Lindbæk holds a master’s degree in Comparative Politics from the University of Bergen and London School of Economics.

Contacts

Investor relations:

Peter Hutton, senior vice president, Investor Relations,
+44 7881 918792 (mobile)

Media relations:

Bård Glad Pedersen, vice president, Media Relations,
+47 918 01 791 (mobile)

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment



Study Investigates Effects of Patient Blood Management Program with Masimo SpHb®, Noninvasive, Continuous Hemoglobin Monitoring, on Postoperative Cancer Patients

Study Investigates Effects of Patient Blood Management Program with Masimo SpHb®, Noninvasive, Continuous Hemoglobin Monitoring, on Postoperative Cancer Patients

Patient Blood Management with Masimo SpHb Increased Transfusion Appropriateness and Decreased RBC Units Transfused per Patient

NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) announced today the findings of a study published in Blood Transfusion in which Dr. Lucia Merolle and colleagues at the Azienda USL-IRCCS of Reggio Emilia, Italy investigated the impact of applying a patient blood management program, including use of noninvasive and continuous hemoglobin monitoring, Masimo SpHb®, to the care of postoperative cancer patients.1 The study found that using SpHb as part of a patient blood management program not only increased how often postoperative blood transfusions were appropriate, but decreased the total and mean number of blood units transfused per patient.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201115005174/en/

Masimo Radical-7® with SpHb® (Photo: Business Wire)

Masimo Radical-7® with SpHb® (Photo: Business Wire)

Patient blood management (PBM) is “an evidence-based, multidisciplinary approach aimed at optimizing the care of patients who might need blood transfusions.” Recognizing that PBM might have specific benefits for surgical oncology patients, the researchers implemented a two-step PBM program and compared three groups of postoperative adult cancer patients who underwent major surgery between 2014 and 2017. Step 1 PBM included seminars and training designed to teach semi-intensive post-surgical personnel the principles of PBM. Step 2 PBM added the use of SpHb monitored with Masimo Radical-7® Pulse CO-Oximeters® with SpHb. Audit 1 reviewed data for 200 patients whose post-surgical care did not incorporate PBM. Audit 2 was of 200 patients whose care incorporated Stage 1 PBM, and Audit 3 was of 200 patients whose care incorporated Stage 2 PBM along with continuous SpHb monitoring.

Using guidelines developed by the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI), the researchers found that transfusion appropriateness rose from 38% in Audit 1 patients, to 75% in Audit 2 patients (Step 1 PBM), to 79% in Audit 3 patients (Step 2 PBM, with SpHb). The total number of red blood cell (RBC) units transfused was similar for Audit 1 and Audit 2 patients (52 and 58 units, respectively), but dropped to 39 units with the addition of SpHb monitoring to PBM (Audit 3). The mean number of RBC units transfused was the same for Audit 1 and Audit 2 patients (1.8 units/patient), but again, with the addition of SpHb monitoring (Audit 3), the mean dropped to 1.3 units/patient.

The researchers concluded, “Our PBM bundle positively impacted RBC transfusion appropriateness in post-surgical cancer patients, both in terms of quality and quantity. A structured PBM program specifically dedicated to surgical oncology should cover the entire perioperative period and might further improve transfusion appropriateness in these patients. The publication of guidelines on the management of anemia in surgical oncology should be a priority.”

In other clinical studies, continuous monitoring with SpHb as part of PBM programs has been found to improve outcomes, such as reducing the percentage of patients receiving transfusions,2 reducing the units of red blood cells transfused per patient,3-4 reducing the time to transfusion,5 reducing costs,6 and even reducing mortality 30 and 90 days after surgery by 33% and 29%, respectively.7 With the addition of the Italian study, the evidence of SpHb’s impact on outcomes spans the globe, representing 6 countries on 4 different continents.1-7 Today, SpHb technology supports clinicians in over 75 countries around the world.8

SpHb is not intended to replace laboratory blood testing. Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering, among other factors, patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.9 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,10 improve CCHD screening in newborns,11 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.12-15 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,16 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.17 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Merolle L, Marraccini C, Di Bartolomeo E, Montella M, Pertinhez T, Baricchi R, Bonini A. Postoperative patient blood management: transfusion appropriateness in cancer patients. Blood Transfus 2020; 18: 359-65 DOI 10.2450/2020.0048-20.
  2. Ehrenfeld JM et al. Continuous Non-invasive Hemoglobin Monitoring during Orthopedic Surgery: A Randomized Trial. J Blood Disorders Transf. 2014. 5:9. 2.
  3. Awada WN et al. Continuous and noninvasive hemoglobin monitoring reduces red blood cell transfusion during neurosurgery: a prospective cohort study. J Clin Monit Comput. 2015 Feb 4.
  4. Imaizumi et al. Continuous and noninvasive hemoglobin monitoring may reduce excessive intraoperative RBC transfusion. Proceedings from the 16th World Congress of Anaesthesiologists, Hong Kong. Abstract #PR607.
  5. Kamal AM et al. The Value of Continuous Noninvasive Hemoglobin Monitoring in Intraoperative Blood Transfusion Practice During Abdominal Cancer Surgery. Open J Anesth. 2016;13-19.
  6. Ribed-Sánchez B et al. Economic Analysis of the Reduction of Blood Transfusions during Surgical Procedures While Continuous Hemoglobin Monitoring is Used. Sensors. 2018, 18, 1367; doi:10.3390/s18051367.
  7. Cros J et al. Continuous hemoglobin and plethysmography variability index monitoring can modify blood transfusion practice and is associated with lower mortality. J Clin Monit Comp. 3 Aug 2019. https://doi.org/10.1007/s10877-019-00367-z.
  8. Masimo data on file.
  9. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  10. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  11. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  12. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  13. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  14. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  15. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  16. Estimate: Masimo data on file.
  17. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SpHb®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo SpHb, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo

Evan Lamb
949-396-3376

[email protected]

KEYWORDS: North America United States Switzerland Europe Italy California

INDUSTRY KEYWORDS: Biotechnology Surgery Medical Devices Health Oncology

MEDIA:

Logo
Logo
Photo
Photo
Masimo Radical-7® with SpHb® (Photo: Business Wire)

New Maginito Website and Presentation

LONDON and VANCOUVER, British Columbia, Nov. 16, 2020 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango”) is pleased to announce the launch of a new website for Maginito Limited (“Maginito”) (www.maginito.com), together with a new Maginito company presentation, available for download from the website via the following link: https://maginito.com/site/assets/files/1/20201103_maginito_presentation-1.pdf

Maginito is 75.5% owned by Mkango, which is completing a Feasibility Study for the Songwe Hill rare earths project in Malawi, and 24.5% owned by Talaxis Limited (“Talaxis”), which is focused on investment in and development of technology metal opportunities.

Maginito was established to pursue downstream green technology opportunities in the rare earths supply chain, encompassing neodymium (NdFeB) magnet recycling as well as innovative rare earth alloy, magnet and separation technologies.

Maginito’s strategy is underpinned by offtake rights for sustainably sourced primary and secondary raw materials, and geared to accelerating growth in the electric vehicle sector, wind power generation and other industries driven by decarbonisation of the economy.

In January 2020, Maginito acquired a 25% interest in UK based NdFeB magnet recycler, HyProMag Limited (“HyProMag”), with an option to increase to 49%. HyProMag is focused on short loop NdFeB magnet recycling using a hydrogen-based technology (HPMS) developed at the Magnetic Materials Group (MMG) within the University of Birmingham. HyProMag is a partner in the Innovate UK grant funded project, “Rare-Earth Recycling for E-Machines” (“RaRE”) together with University of Birmingham, Advanced Electric Machines Research Limited, Bentley Motors Limited, Intelligent Lifecycle Solutions Limited and Unipart Powertrain Applications Limited, which will for the first time establish an end to end supply chain to incorporate recycled rare earth magnets into electric vehicles.

Maginito is currently evaluating a number of other complementary downstream technology opportunities.

About
HyProMag

The Magnetic Materials Group within the School of Metallurgy and Materials at the University of Birmingham has been active in the field of rare earth alloys and processing of permanent magnets using hydrogen for over 40 years. Originated by Professor Rex Harris, the hydrogen decrepitation method, which is used to reduce NdFeB alloys to a powder, is now ubiquitously employed in worldwide magnet processing.

In a further development, the MMG patented a process for extracting and demagnetising NdFeB powders from magnets embedded in redundant equipment using hydrogen in a process called HPMS (Hydrogen Processing of Magnet Scrap). This patent and related intellectual property is at the core of HyProMag’s business. The MMG continues to develop new research and development opportunities, cooperates widely in Europe, including a major EU project, SusMagPro, which is also focused on recycling of magnets. The directors of HyProMag all provide their expertise to the MMG and there is potential for HyProMag to gain possible future access to new intellectual property.

HyProMag is also a partner in the Innovate UK grant funded project, “Rare-Earth Recycling for E-Machines” (“RaRE”) together with University of Birmingham, Advanced Electric Machines Research Limited, Bentley Motors Limited, Intelligent Lifecycle Solutions Limited and Unipart Powertrain Applications Limited.

RaRE will for the first time establish an end to end supply chain to incorporate recycled rare earth magnets into electric vehicles, whereby recycled magnets will be built into an ancillary electric motor to ultimately support the development of a commercial ancillary motor suite.

HyProMag’s strategy is to establish a recycling facility for NdFeB magnets at Tyseley in Birmingham to provide a sustainable solution for the supply of NdFeB magnets and alloy powders for a wide range of markets including, for example, automotive and electronics. A number of product options are being evaluated including hydrogen decrepitated (HD) demagnetised powders suitable for magnet producers, alloy ingot remelted from HD powders suitable for alloy feed or magnet production, anisotropic alloy powders (HDDR) for bonded magnets and sintered NdFeB magnets as required by the RaRE project for automotive applications.

The founding directors of HyProMag, comprising Professor Emeritus Rex Harris, former Head of the MMG, Professor Allan Walton, current Head of the MMG, and two Honorary Fellows, Dr John Speight and Mr David Kennedy, are leading world experts in the field of rare earth magnetic materials, alloys and hydrogen technology, and have significant industry experience. Following the investment by Maginito, HyProMag appointed William Dawes, a Director of Maginito and Chief Executive Officer of Mkango, to the Board of HyProMag.

For more information, please visit https://hypromag.com/ 

A
bou
t
M
k
an
go

Mkango’s primary business is exploration for rare earth elements and associated minerals in the Republic of Malawi, a country whose hospitable people have earned it a reputation as “the warm heart of Africa”. The Company holds interests in four exclusive prospecting licenses in Malawi: the Phalombe licence, the Thambani licence, the Chimimbe Hill licence and the Mchinji licence.

The main exploration target in the 51% held Phalombe licence is the Songwe Hill rare earths deposit. This features carbonatite-hosted rare earth mineralisation and was subject to previous exploration in the late 1980s. Mkango completed an updated Pre-Feasibility Study for the project in November 2015 and a Feasibility Study is currently underway, the initial phases of which included a 10,900 metre drilling programme and an updated mineral resource estimate, announced in February 2019. In March 2019, the Company announced receipt of a £7 million (C$12.3 million) investment from Talaxis to fund completion of the Feasibility Study. Following completion of the Feasibility Study, Talaxis has an option to acquire a further 26% interest in Songwe by arranging financing for project development including funding the equity component thereof.

The main exploration targets in Mkango’s remaining three 100% held licences are, in the Thambani licence, uranium, niobium, tantalum and zircon, in the Chimimbe Hill licence, nickel and cobalt, and in the Mchinji licence, rutile, nickel, cobalt, base metals and graphite. Mkango recently announced commencement of an extensive exploration program following a new rutile discovery within the Mchinji licence.

Mkango also holds a 75.5% interest in Maginito with the balance owned by Talaxis. Maginito is focused on downstream opportunities relating to the rare earths supply chain, in particular, recycling and other innovative technologies for the production of neodymium alloy powders and magnets used in electric vehicles, wind turbines and other industries geared to decarbonisation of the economy.

For more information, please visit www.mkango.ca

About
Talaxis

Founded in 2016, Talaxis is a wholly-owned subsidiary of Noble Group Holdings Limited and invests in and develops projects that are related to technology metals, with a special focus on rare earth elements. Talaxis focuses on battery and electric vehicle materials such as nickel, lithium, graphite and vanadium. Talaxis has supply chain partners in the upstream and midstream segments, and also focuses on research and development solutions for industrial consumers in the downstream segment. Talaxis prioritises sustainable ventures with a strong emphasis on corporate social responsibility. These include projects that contribute to the decarbonisation of the economy and that are aligned with the United Nations Sustainable Development Goals.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements (within the meaning of that term under applicable securities laws) with respect to Mkango, its business and the Project. Generally, forward looking statements can be identified by the use of words such as “plans”, “expects” or “is expected”, “scheduled”, “estimates” “intends”, “anticipates”, “believes”, or variations of such words and phrases, or statements that certain actions, events or results “can”, “may”, “could”, “would”, “should”, “might” or “will”, occur or be achieved, or the negative connotations thereof. Forward looking statements in this news release include statements with respect to the global market for rare earth metals, completion of the feasibility study for Songwe, investments by Maginito in Hypromag and of the plans and results with respect to Maginito and HyProMag, as well as plans for Tyseley. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. Such factors and risks include, without limiting the foregoing, governmental action relating to COVID-19, COVID-19 and other market effects on global demand for the metals and associated downstream products for which Mkango is exploring, researching and developing, the positive results of a feasibility study on the Project and delays in obtaining financing or governmental or stock exchange approvals. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

For further information on Mkango, please contact:
 
Mkango Resources Limited
William Dawes   Alexander Lemon
Chief Executive Officer   President

[email protected]
 
[email protected]
 
Canada: +1 403 444 5979    
     

www.mkango.ca
  
@MkangoResources   
     
Blytheweigh   
Financial Public Relations   
Tim Blythe   
UK: +44 207 138 3204   
     
SP Angel Corporate Finance LLP   
Nominated Adviser and Joint Broker   
Jeff Keating, Caroline Rowe   
UK: +44 20 3470 0470   
     
Alternative Resource Capital   
Joint Broker   
Alex Wood   
UK: +44 20 7186 9004   


The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any equity or other securities of the Company in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.



PureTech to Present at Three Upcoming Investor Conferences

PureTech to Present at Three Upcoming Investor Conferences

BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that members of the Management Team will present at the following upcoming virtual investor conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com.

Jefferies 2020 Virtual London Healthcare Conference

Presenter: Daphne Zohar, founder and chief executive officer

Date: Wednesday, November 18, 2020

Time: 9:05 AM EST

Piper Sandler 32nd Annual Virtual Healthcare Conference

Presenters: Daphne Zohar, founder and chief executive officer; Eric Elenko, chief innovation officer

Date: Fireside Chat available as of 10:00 AM EST on Monday, November 23, 2020

Evercore ISI 3rd Annual HealthCONx Conference

Presenters: Daphne Zohar, founder and chief executive officer; Eric Elenko, chief innovation officer

Date: Thursday, December 3, 2020

Time: 4:20 PM EST

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 24 products and product candidates, including two that have received U.S. Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company’s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Investors

Allison Mead Talbot

+1 617 651 3156

[email protected]

U.S. Media

Stephanie Simon

+1 617 581 9333

[email protected]

KEYWORDS: Europe United States United Kingdom North America Massachusetts

INDUSTRY KEYWORDS: Medical Devices Health Technology Software Pharmaceutical Biotechnology

MEDIA:

Logo
Logo